Syndax(SNDX)
搜索文档
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Prnewswire· 2024-06-04 04:05
WALTHAM, Mass., June 3, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on June 1, 2024 the Company granted inducement awards to purchase up to 499,200 shares of common stock to fifty-three new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting comme ...
Syndax(SNDX) - 2024 Q1 - Earnings Call Transcript
2024-05-09 04:08
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - CEO & Director Steve Closter - Chief Commercial Officer Keith Goldan - CFO Neil Gallagher - President, Head of Research and Development Anjali Ganguli - Chief Business Officer Conference Call Participants Peter Lawson - Barclays Capital Anupam Rama - JPMorgan Securities Brad Canino - Stifel, Nicolaus & Company Phil Nadeau - Cowen & ...
Syndax(SNDX) - 2024 Q1 - Quarterly Report
2024-05-08 19:04
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37708 Syndax Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 32-0162505 (State or Other J ...
Syndax(SNDX) - 2024 Q1 - Quarterly Results
2024-05-08 19:03
Exhibit 99.1 Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update – NDA filing for revumenib in R/R KMT2Ar acute leukemia granted Priority Review under RTOR; PDUFA action date set for September 26, 2024 – – BLA filing for axatilimab in chronic GVHD granted Priority Review; PDUFA action date set for August 28, 2024 – – Enrollment completed in AUGMENT-101 mNPM1 cohort; topline data expected in 4Q24 to potentially support sNDA filing in 1H25 – – Company ...
Syndax(SNDX) - 2023 Q4 - Earnings Call Presentation
2024-02-28 10:21
SNDX Fourth Quarter and Full Year 2023 Results / February 27, 2024 Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events, progress, timing or circumstances) are intended to identify forward-looking statements. All statements other than statements of ...
Syndax(SNDX) - 2023 Q4 - Earnings Call Transcript
2024-02-28 10:21
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive Officer Dr. Neil Gallagher - President and Head, R&D Keith Goldan - Chief Financial Officer Dr. Peter Ordentlich - Chief Scientific Officer Dr. Anjali Ganguli - Chief Business Officer Conference Call Participants Anupam Rama - JPMorgan Phil Nadeau - TD Cowen Brad Canino - Stifel Michael Schmidt - Guggenheim As ...
Syndax(SNDX) - 2023 Q4 - Annual Report
2024-02-28 05:33
UNITED8 4,82 6,63 S2 TATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-37708 Syndax Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 2834 32-0162505 (Sta ...
Syndax(SNDX) - 2023 Q4 - Annual Results
2024-02-28 05:03
Exhibit 99.1 Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update – BLA filing for axatilimab in chronic GVHD granted Priority Review; PDUFA action date set for August 28, 2024 – – NDA for revumenib in R/R KMT2Ar acute leukemia submitted under FDA’s RTOR program; PDUFA date assignment expected in 1Q24 – – Enrollment in AUGMENT-101 mNPM1 patient cohort expected to complete in late 1Q/early 2Q; topline data in 4Q24 – – Initiated revumenib ...
Syndax(SNDX) - 2023 Q3 - Earnings Call Transcript
2023-11-03 09:26
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Q3 2023 Results Conference Call November 2, 2023 4:30 PM ET Company Participants Sharon Klahre - Head of Investor Relations Michael Metzger - Chief Executive Officer Neil Gallagher - President and Head of R&D Keith Goldan - Chief Financial Officer Peter Ordentlich - Chief Scientific Officer Anjali Ganguli - Chief Business Officer Conference Call Participants Brad Canino - Stifel Phil Nadeau - TD Cowen Peter Lawson - Barclays Michael Schmidt - Guggenheim Kalpit Patel ...
Syndax(SNDX) - 2023 Q3 - Quarterly Report
2023-11-03 04:05
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37708 Syndax Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 32-0162505 (State or Oth ...